A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer

BACKGROUND: The addition of bevacizumab to standard chemotherapy prolongs progression free survival in the first line treatment of epithelial ovarian cancer (EOC), but its cost/effectiveness is debated. We assessed the safety and activity of a lower dose of bevacizumab in pretreated advanced stage E...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Defferrari, Carlotta, Campora, Sara, D'Amico, Mauro, Piccardo, Arnoldo, Biscaldi, Ennio, Rosselli, Daniela, Pasa, Ambra, Puntoni, Matteo, Gozza, Alberto, Gennari, Alessandra, Zanardi, Silvia, Lionetto, Rita, Bandelloni, Michela, DeCensi, Andrea
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2012
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3408333/
https://ncbi.nlm.nih.gov/pubmed/22732001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1757-2215-5-17
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars